×

Legal Disclaimer: Contents may contain attorney advertising under the laws of some states. Prior results do not guarantee a similar outcome.

  • GEOFFREY MASON

    Partner, Cogent Law Group

    Intellectual Property & Business

    Geoffrey Mason is a serial entrepreneur who is also an attorney, freemium web application innovator, and a biochemist. Geoff has founded multiple companies focused on mining patent-related data for high-value information using both freemium and flat rate business models. He is a licensed intellectual property (“IP”) attorney with decades of experience in all aspects of patent, trademark, copyright, and trade secret protection activities and strategies.

  • ENTREPRENEURIAL AND LEGAL OVERVIEW:

    Geoffrey has advised executives on worldwide IP protection and enforcement and built valuable patent portfolios for major U.S. and international companies. His IP litigation experience includes patent prosecution in the computer, medical, biotech/pharmaceutical, and mechanical arts industries. Geoff also has had successful enforcement of key patents, yielding hundreds of millions of dollars to patentees in either royalties or protected sales. He has worked with over a hundred early-stage technology companies on investments, business contracts, corporate transactions, cryptocurrency specific and general compliance, and cost-effective intellectual property strategies.

     

    Geoff is the founder and CEO of FastPatentPartner and MPA Holdings. In the past, he has served as counsel at Sughrue Mion and as an attorney at Sidley, Austin, and Finnegan, Henderson, Farabow, Garrett and Dunner.

  • EDUCATION

    Georgetown University Law School

    JD, Law 1994-1997

    • Georgetown Law Journal

    Harvard University

    B.A., Biochemical Sciences and Social Studies, 1990-1994

  • PROFESSIONAL EXPERIENCE

    Partner

    2015 - Present

    Serves as general counsel to medical device, pharmaceutical, cryptocurrency, manufacturing, social networking, and other technology companies, with an emphasis on patent and intellectual property strategy and litigation.

    Partner

    2013 - Present

    Serves as lead counsel on all patent litigations and strategic engagements at Moarbes as well as on all general U.S. litigation.

    Founder/CEO of FastPatentPartner

    2008 - Present

    Geoffrey founded FastPatentPartner, LLC and MPA Holdings, LLC to help lawyers win their cases with products that develop key documents and facts like never before using a unique, comprehensive 1.5B page PDF repository of pleadings and file histories, combined with proprietary analytics and web crawling technologies.

    Of Counsel

    2012 - 2015

    Geoffrey managed and tried patent litigations, assisted with patent aspects of corporate acquisitions, and developed prosecution and enforcement strategies for PLG clients.

    Of Counsel

    2011 - 2013

    Geoffrey launched Moarbes' patent and general U.S. litigation practice.

    Of Counsel

    2008 - 2011

    Defended Wockhardt against two Lilly patents covering Duloxetine, a $5 billion a year drug at its peak. Conceived of and developed inequitable conduct and term extension defenses that convinced Wockhardt to litigate solo against Lilly after all remaining defendants ceased to actively litigate, a step Wockhardt has never taken before. Also negotiated a covenant not to sue on an unasserted patent listed in the Orange Book for Duloxetine.

    Associate

    2006 - 2008

    Asserted two patents against defendant Andrx seeking to make generic Concerta. Convinced opposing counsel to drop an enforceability defense immediately after taking a successful deposition of one of their expert witnesses. Was also primarily responsible for developing most of the expert witness positions in the case, working directly with both these experts and the then-head of J&J's Hatch-Waxman practice.

    Associate, Biotechnology/Pharmaceutical Group

    1997 - 2006

    Represented brand companies in Hatch-Waxman litigations relating to many blockbuster drugs, including Prozac, Lovenox, and Augmentin, as well as litigating patents relating to WiFi and internet infrastructure technologies.